Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients.

Aliyev, Elmar R; Hay, Joel W; Hwang, Caroline

Aliyev, Elmar R; Hay, Joel W; Hwang, Caroline.

Affiliation

Aliyev ER; Leonard D. Schaeffer Center for Health Policy & Economics, Los Angeles, California.
Hay JW; Leonard D. Schaeffer Center for Health Policy & Economics, Los Angeles, California.
Hwang C; Inflammatory Bowel Disease Center, Division of Gastrointestinal and Liver Disease, USC/Keck School of Medicine, Los Angeles, California.

Pharmacotherapy ; 39(2): 118-128, 2019 02.

Article in En | MEDLINE | ID: mdl-30565265

Subject(s)

Antibodies, Monoclonal, Humanized/therapeutic use; Crohn Disease/drug therapy; Adalimumab/economics; Adalimumab/therapeutic use; Adult; Antibodies, Monoclonal, Humanized/economics; Biosimilar Pharmaceuticals; Cost-Benefit Analysis; Crohn Disease/pathology; Female; Humans; Infliximab/economics; Infliximab/therapeutic use; Male; Models, Economic; Quality-Adjusted Life Years; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha/antagonists & inhibitors; United States; Ustekinumab/economics; Ustekinumab/therapeutic use

Key words

C-reactive protein; biologics; computer modeling; gastroenterology; pharmacoeconomics; quality of life

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Crohn Disease / Antibodies, Monoclonal, Humanized Type of study: Health_economic_evaluation / Prognostic_studies Limits: Adult / Female / Humans / Male Country/Region as subject: America do norte Language: En Journal: Pharmacotherapy Year: 2019 Type: Article

Fulltext

XML

PubMed Links

Search on Google